* eFFECTOR Therapeutics Inc EFTR.OQ EFTR.O is expected
to show
a rise in quarterly revenue when it reports results on November
7 (estimated).
* The Solana Beach California-based company is expected to
report
a 50.4% increase in revenue to $642.2 thousand from $427
thousand a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for eFFECTOR
Therapeutics Inc
is for a loss of 21 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for eFFECTOR
Therapeutics Inc is $7.5, above its last closing price
of $0.53.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.16 -0.16 -0.17 Missed -5.5
Mar. 31 2022 -0.24 -0.24 0.07 Beat 129.5
Dec. 31 2021 -0.24 0.44 Beat 283.2
Sep. 30 2021 -0.25 -0.20 0.42 Beat 313.6
This summary was machine generated November 4 at 18:31 GMT. All
figures in US dollars unless otherwise stated